Endpoints Media Bias

AI Generated News Bias (?): The source appears to be biased towards biotechnology, with a focus on drug development, clinical trials, and medical treatments ([0], [1], [2], [7], [8], [9], [10], [15], [16], [17], [18], [19], [20], [21], [22], [23]). It also covers some negative news, such as layoffs ([0]) and fraud schemes ([13]).



         

Endpoints Social Media Impact (?): 6


Endpoints Most Opinionated Articles


Trio of biotechs trim their pipelines as rough market not letting up in third quarter

GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup

Adcomm offers mixed vote, recommends GSK's kidney disease drug in just one patient population

FDA commissioner calls for more onshoring of clinical trials


Endpoints Most Subjective Articles


Trio of biotechs trim their pipelines as rough market not letting up in third quarter

Chris Viehbacher once again sets out to revamp R&D at a major biopharma. The last try led to his ouster

Special report 2022: Meet 20 women blazing trails in biopharma RD

Amgen may be way late to the obesity game, but the market scouts are loving the blockbuster potential of AMG 133


Endpoints Most Fearful Articles


ObsEva, desperate for cash, sells rights to PhII drug in bid to extend runway, test new pregnancy candidate

Bayer CEO talks next steps on inflation, supply chain stability amid Q3 growth


Endpoints Most Gossipy Articles


Scoop: Gilead terminates early-stage FLT3 trial in solid tumors

Scoop: Rakuten billionaire lines up $70M for photoimmunotherapy

Scoop: Avalon, MPM back new CNS biotech with scientific chops from Astellas - Endpoints News

Following Alzheimer's drug approval, analysts dish on what they ...




Endpoints Most Prescriptive Articles


As Revlimid faces more competition, Bristol Myers' goal is to 'grow the company' - Endpoints News

Alex Harding to chase industry dreams at CRISPR Therapeutics ... - Endpoints News

Indivior snaps up Narcan owner for $145M upfront, with an eye on next-gen nasal spray

Amgen may be way late to the obesity game, but the market scouts are loving the blockbuster potential of AMG 133

Bayer CEO talks next steps on inflation, supply chain stability amid Q3 growth

Clinical trial coordinators sentenced to prison after data falsification scheme

Athenex to exit drug compounding business and axe 92 employees at NY plant

CSL lands FDA approval for hemophilia B gene therapy, sets $3.5M list price



Endpoints Recent Articles